Great to have part ownership in a business which already has runs on the board (170 sites and growing) with further growth catalysts to follow and this calendar year..
The Stryker relationship should be pivotal to an increase in QoQ numbers.
The planned introduction of a SaaS business model with stated high margins should propel interest in this medical AI business. Last Directors Report in Annual Report is compelling in its outlook.
Cannot discount Stryker positioning itself for a corporate play when earnings in SaaS are more evident following regulatory process ticked off.
Seems we have an underestimated value given speculative nature much diminished. AIMO
Add to My Watchlist
What is My Watchlist?
